COMPARISON
Octreotide vs Tesamorelin
6 attributes held for at least one of the two. 6 differ. Each value carries the register it came from and the date that register was read.
Answer
Octreotide is authorised or registered in 10 and Tesamorelin in 2 of the 10 registers read. Octreotide: highest phase Phase 4 (after approval). Tesamorelin: No trial states a phase. 0 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Octreotide | Tesamorelin | |
|---|---|---|
| Registered trials differs | 344 clinicaltrials.gov · 2026-10-03 | 24 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: Octreotide Acetate openfda · 2026-10-03T17:23:44.062Z | FDA-approved: EGRIFTA SV openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation differs | Authorised ema · 2026-10-03 | Application withdrawn ema · 2026-10-03 |
| EU authorised on differs | 2025-06-30 ema · 2026-10-03 | Not checked no record of "authorisedOn" for tesamorelin |
| EU withdrawn on differs | 2022-12-02 ema · 2026-10-03 | Not checked no record of "withdrawnOn" for tesamorelin |
| ATC code differs | H01CB02 ema · 2026-10-03 | Not checked no record of "atcCode" for tesamorelin |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Octreotide | placebo | Tesamorelin | placebo |
|---|---|---|---|---|
| Diarrhoea | 46.2% | 31.7% | - | - |
| Oedema peripheral | 34.9% | 19.6% | - | - |
| Asthenia | 33.3% | 20.9% | - | - |
| Nausea | 30.8% | 21.2% | - | - |
| Fatigue | 29.8% | 27.7% | - | - |
| Rash | 28.8% | 14.1% | - | - |
| Decreased appetite | 28.5% | 15.2% | - | - |
| Hypertension | 26.5% | 19.4% | - | - |
| Dyspnoea | 25.9% | 9.1% | - | - |
| Anaemia | 24.3% | 9.1% | - | - |
| Injection site erythema | - | - | 6.8% | 2.6% |
| Paresthesia | - | - | 2.4% | 5.0% |
| Injection site pain | - | - | 1.8% | 2.5% |
| Nephrolithiasis | - | - | 0.8% | 0.5% |
| Abdominal pain | - | - | 0.6% | 1.5% |
Trial register Octreotide: 5 placebo-controlled trials; Tesamorelin: 4. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Octreotide side effects · Tesamorelin side effects
LEGAL STATUS
Approval in each country read
| Country | Octreotide | Tesamorelin | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Authorised | Application withdrawn | Regulator EMA |
| United Kingdom | Authorised | Not on the register | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Registered | Status unknown | Regulator TGA |
| Switzerland | Authorised | Not on the register | Regulator Swissmedic |
| Brazil | Registado | Not on the register | Regulator ANVISA |
| Serbia | Authorised | Not on the register | Regulator ALIMS |
| Singapore | Registered | Not on the register | Regulator HSA |
| Turkey | Ruhsatli | Not on the register | Regulator TITCK |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.